Thank you, Mr. Chair.
Madam Stoddart, on this whole question of privacy, it seems to me that this is often used as an excuse by industry for not giving open, frank, transparent information about adverse reactions, about problems with drugs, about safety issues. How do we prevent that? How do we separate out the legitimate concerns around privacy from the need for an open, transparent system?